Serrated Polyposis Syndrome

  • Sabela Carballal
  • Francesc Balaguer
  • Antoni Castells


Serrated polyps (SPs) are considered the precursor lesions of up to 15–30% of all colorectal carcinomas through the “serrated neoplasia pathway.” Serrated polyposis syndrome (SPS), characterized by the presence large and/or numerous serrated lesions spreading throughout the colorectum, is emerging as one of the most common colorectal cancer polyp syndromes. This condition is associated with an increased personal and familial colorectal cancer risk. Clinical management includes yearly surveillance colonoscopy and surgery. Although the majority of cases occur in patients older than 50 years old with no family history of CRC, several lines of evidence support that a proportion of SPS could be the phenotypic expression of an inherited genetic syndrome, but the genetic basis for SPS remains elusive. Recent studies provided proof of the pathogenicity of RNF43 germline mutation in a small subset of patients. Future research in SPS should be focused on understanding the phenotype and clinical management and on unraveling the pathogenesis of the syndrome.


Serrated polyp Hyperplastic polyp Polyposis Colorectal carcinogenesis Serrated pathway 


  1. 1.
    Winawer SJ, Zauber AG, Ho MN, O'Brien MJ, Gottlieb LS, Sternberg SS, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med. 1993;329(27):1977–81. Scholar
  2. 2.
    Muto T, Bussey HJ, Morson BC. The evolution of cancer of the colon and rectum. Cancer. 1975;36(6):2251–70.CrossRefGoogle Scholar
  3. 3.
    Leggett B, Whitehall V. Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology. 2010;138(6):2088–100. S0016-5085(10)00172-1 [pii]. Scholar
  4. 4.
    Snover DC. Update on the serrated pathway to colorectal carcinoma. Hum Pathol. 2011;42(1):1–10. S0046-8177(10)00206-6 [pii]. Scholar
  5. 5.
    Rex DK, Ahnen DJ, Baron JA, Batts KP, Burke CA, Burt RW, et al. Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol. 2012;107(9):1315–29; quiz 4, 30. doi:ajg2012161 [pii]. Scholar
  6. 6.
    Oono Y, Fu K, Nakamura H, Iriguchi Y, Yamamura A, Tomino Y, et al. Progression of a sessile serrated adenoma to an early invasive cancer within 8 months. Dig Dis Sci. 2009;54(4):906–9. Scholar
  7. 7.
    Lash RH, Genta RM, Schuler CM. Sessile serrated adenomas: prevalence of dysplasia and carcinoma in 2139 patients. J Clin Pathol. 2010;63(8):681–6. jcp.2010.075507 [pii]. Scholar
  8. 8.
    IJspeert J, Bevan R, Senore C, Kaminski MF, Kuipers EJ, Mroz A, et al. Detection rate of serrated polyps and serrated polyposis syndrome in colorectal cancer screening cohorts: a European overview. Gut. 2016. gutjnl-2015-310784 [pii].
  9. 9.
    Lockett MJ, Atkin WS. Hyperplastic polyposis: prevalence and cancer risk. Gut. 2001;48(Supl 1):A4.Google Scholar
  10. 10.
    Hyman NH, Anderson P, Blasyk H. Hyperplastic polyposis and the risk of colorectal cancer. Dis Colon Rectum. 2004;47(12):2101–4. Scholar
  11. 11.
    Boparai KS, Mathus-Vliegen EM, Koornstra JJ, Nagengast FM, van Leerdam M, van Noesel CJ, et al. Increased colorectal cancer risk during follow-up in patients with hyperplastic polyposis syndrome: a multicentre cohort study. Gut. 2010;59(8):1094–100. gut.2009.185884 [pii]. Scholar
  12. 12.
    Hazewinkel Y, Tytgat KM, van Eeden S, Bastiaansen B, Tanis PJ, Boparai KS, et al. Incidence of colonic neoplasia in patients with serrated polyposis syndrome who undergo annual endoscopic surveillance. Gastroenterology. 2014;147(1):88–95. S0016-5085(14)00364-3 [pii]. Scholar
  13. 13.
    Orlowska J. Hyperplastic polyposis syndrome and the risk of colorectal cancer. Gut. 2012;61(3):470–1.; author reply 1–2. gutjnl-2011-300141 [pii]. Scholar
  14. 14.
    Rubio CA, Stemme S, Jaramillo E, Lindblom A. Hyperplastic polyposis coli syndrome and colorectal carcinoma. Endoscopy. 2006;38(3):266–70. Scholar
  15. 15.
    Moreira L, Pellise M, Carballal S, Bessa X, Ocana T, Serradesanferm A, et al. High prevalence of serrated polyposis syndrome in FIT-based colorectal cancer screening programmes. Gut. 2013;62(3):476–7. gutjnl-2012-303496 [pii]. Scholar
  16. 16.
    Biswas S, Ellis AJ, Guy R, Savage H, Madronal K, East JE. High prevalence of hyperplastic polyposis syndrome (serrated polyposis) in the NHS bowel cancer screening programme. Gut. 2013;62(3):475. gutjnl-2012-303233 [pii]. Scholar
  17. 17.
    Ferrandez A, Samowitz W, DiSario JA, Burt RW. Phenotypic characteristics and risk of cancer development in hyperplastic polyposis: case series and literature review. Am J Gastroenterol. 2004;99(10):2012–8. AJG30021 [pii]CrossRefPubMedGoogle Scholar
  18. 18.
    Lage P, Cravo M, Sousa R, Chaves P, Salazar M, Fonseca R, et al. Management of Portuguese patients with hyperplastic polyposis and screening of at-risk first-degree relatives: a contribution for future guidelines based on a clinical study. Am J Gastroenterol. 2004;99(9):1779–84. AJG30178 [pii]CrossRefPubMedGoogle Scholar
  19. 19.
    Chow E, Lipton L, Lynch E, D'Souza R, Aragona C, Hodgkin L, et al. Hyperplastic polyposis syndrome: phenotypic presentations and the role of MBD4 and MYH. Gastroenterology. 2006;131(1):30–9. S0016-5085(06)00713-X [pii]. Scholar
  20. 20.
    Kalady MF, Jarrar A, Leach B, LaGuardia L, O'Malley M, Eng C, et al. Defining phenotypes and cancer risk in hyperplastic polyposis syndrome. Dis Colon Rectum. 2011;54(2):164–70. 00003453-201102000-00007 [pii]CrossRefPubMedGoogle Scholar
  21. 21.
    Navarro M, Gonzalez S, Iglesias S, Capella G, Rodriguez-Moranta F, Blanco I. Hyperplastic polyposis syndrome: phenotypic diversity and association to colorectal cancer. Med Clin (Barc). 2013;141(2):62–6. S0025-7753(12)00512-X [pii]. Scholar
  22. 22.
    Carballal S, Rodriguez-Alcalde D, Moreira L, Hernandez L, Rodriguez L, Rodriguez-Moranta F, et al. Colorectal cancer risk factors in patients with serrated polyposis syndrome: a large multicentre study. Gut. 2015. gutjnl-2015-309647 [pii].
  23. 23.
    Ijspeert J, Rana SA, Atkinson NS, van Herwaarden YJ, Bastiaansen BA, van Leerdam ME, et al. Clinical risk factors of colorectal cancer in patients with serrated polyposis syndrome: a multicentre cohort analysis. Gut. 2015. gutjnl-2015-310630 [pii].
  24. 24.
    Buchanan DD, Sweet K, Drini M, Jenkins MA, Win AK, Gattas M, et al. Phenotypic diversity in patients with multiple serrated polyps: a genetics clinic study. Int J Color Dis. 2010;25(6):703–12. CrossRefGoogle Scholar
  25. 25.
    IJspeert J, Bossuyt PM, Kuipers EJ, Stegeman I, de Wijkerslooth TR, Stoop EM, et al. Smoking status informs about the risk of advanced serrated polyps in a screening population. Endosc Int Open. 2016;4(1):E73–8. Scholar
  26. 26.
    Boparai KS, Reitsma JB, Lemmens V, van Os TA, Mathus-Vliegen EM, Koornstra JJ, et al. Increased colorectal cancer risk in first-degree relatives of patients with hyperplastic polyposis syndrome. Gut. 2010;59(9):1222–5. gut.2009.200741 [pii]. Scholar
  27. 27.
    Oquinena S, Guerra A, Pueyo A, Eguaras J, Montes M, Razquin S, et al. Serrated polyposis: prospective study of first-degree relatives. Eur J Gastroenterol Hepatol. 2013;25(1):28–32. CrossRefPubMedGoogle Scholar
  28. 28.
    Lieberman DA, Rex DK, Winawer SJ, Giardiello FM, Johnson DA, Levin TR. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2012;143(3):844–57. S0016-5085(12)00812-8 [pii]. Scholar
  29. 29.
    Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110(2):223–62.; quiz 63. ajg2014435 [pii]. Scholar
  30. 30.
    Stefanius K, Ylitalo L, Tuomisto A, Kuivila R, Kantola T, Sirnio P, et al. Frequent mutations of KRAS in addition to BRAF in colorectal serrated adenocarcinoma. Histopathology. 2011;58(5):679–92. Scholar
  31. 31.
    Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer. 2004;4(12):937–47. nrc1503 [pii]. Scholar
  32. 32.
    Kim KM, Lee EJ, Ha S, Kang SY, Jang KT, Park CK, et al. Molecular features of colorectal hyperplastic polyps and sessile serrated adenoma/polyps from Korea. Am J Surg Pathol. 2011;35(9):1274–86. Scholar
  33. 33.
    Moran A, Ortega P, de Juan C, Fernandez-Marcelo T, Frias C, Sanchez-Pernaute A, et al. Differential colorectal carcinogenesis: molecular basis and clinical relevance. World J Gastrointest Oncol. 2010;2(3):151–8. Scholar
  34. 34.
    Yamane L, Scapulatempo-Neto C, Reis RM, Guimaraes DP. Serrated pathway in colorectal carcinogenesis. World J Gastroenterol. 2014;20(10):2634–40. Scholar
  35. 35.
    Rosty C, Parry S, Young JP. Serrated polyposis: an enigmatic model of colorectal cancer predisposition. Pathol Res Int. 2011;2011:157073. Scholar
  36. 36.
    Win AK, Walters RJ, Buchanan DD, Jenkins MA, Sweet K, Frankel WL, et al. Cancer risks for relatives of patients with serrated polyposis. Am J Gastroenterol. 2012;107(5):770–8. ajg201252 [pii]. Scholar
  37. 37.
    Gala MK, Mizukami Y, Le LP, Moriichi K, Austin T, Yamamoto M, et al. Germline mutations in oncogene-induced senescence pathways are associated with multiple sessile serrated adenomas. Gastroenterology. 2014;146(2):520–9. S0016-5085(13)01519-9 [pii]. Scholar
  38. 38.
    de Lau W, Peng WC, Gros P, Clevers H. The R-spondin/Lgr5/Rnf43 module: regulator of Wnt signal strength. Genes Dev. 2014;28(4):305–16. 28/4/305 [pii]. Scholar
  39. 39.
    Koo BK, Spit M, Jordens I, Low TY, Stange DE, van de Wetering M, et al. Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors. Nature. 2012;488(7413):665–9. nature11308 [pii]. Scholar
  40. 40.
    Taupin D, Lam W, Rangiah D, McCallum L, Whittle B, Zhang Y, et al. A deleterious RNF43 germline mutation in a severely affected serrated polyposis kindred. Hum Genome Var. 2015;2:15013. CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Yan HH, Lai JC, Ho SL, Leung WK, Law WL, Lee JF, et al. RNF43 germline and somatic mutation in serrated neoplasia pathway and its association with BRAF mutation. Gut. 2016. gutjnl-2016-311849 [pii].
  42. 42.
    Sekine S, Yamashita S, Tanabe T, Hashimoto T, Yoshida H, Taniguchi H, et al. Frequent PTPRK-RSPO3 fusions and RNF43 mutations in colorectal traditional serrated adenoma. J Pathol. 2016;239(2):133–8. Scholar
  43. 43.
    Buchanan DD, Clendenning M, Zhuoer L, Stewart JR, Joseland S, Woodall S, et al. Lack of evidence for germline RNF43 mutations in patients with serrated polyposis syndrome from a large multinational study. Gut. 2016. gutjnl-2016-312773 [pii].
  44. 44.
    IJspeert J, van Doorn SC, van der Brug YM, Bastiaansen BA, Fockens P, Dekker E. The proximal serrated polyp detection rate is an easy-to-measure proxy for the detection rate of clinically relevant serrated polyps. Gastrointest Endosc. 2015;82(5):870–7. S0016-5107(15)00216-3 [pii]. Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Sabela Carballal
    • 1
  • Francesc Balaguer
    • 1
  • Antoni Castells
    • 1
  1. 1.Gastroenterology Department, Hospital Clínic de Barcelona, Centro de Investigación, Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd)Institut d’Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Universitat de BarcelonaBarcelonaSpain

Personalised recommendations